Sign in

NCT07161440Completed

Steroid Profiles in PCOS and Effect of OCP Treatment

Steroid Profiling in Adolescents and Young Women With PCOS: Effects of Oral Contraceptive Therapy Assessed by LC-MS/MS

Source: ClinicalTrials.gov · Last updated 8 Sept 2025

Brief summary (registry, in English)

This prospective observational study investigates the changes in serum steroid intermediates assessed by liquid chromatography-mass spectrometry (LC-MS/MS) in adolescents and young women with polycystic ovary syndrome (PCOS), before and after oral contraceptive (OCP) treatment.

Status (registry)
Completed
Study type
Observational
Enrollment
56 (actual)
First submitted
30 Aug 2025
Start date
2 Jan 2021
Primary completion date
1 Jul 2024
Lead sponsor
Istanbul University
NCT number
NCT07161440

What you commit to

  • Study type: Observational
  • Participants enrolled: 56
  • From 2 Jan 2021 to the primary completion date, 1 Jul 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Use of hormonal medications within 1 year prior to baseline

Other illness

  • Cushing's syndrome

Other

  • Congenital adrenal hyperplasia
  • Pregnancy

Who the study is looking for

  • Diagnosis of PCOS based on Rotterdam criteria
  • Age between 13 and 21 years
  • No hormonal treatment in the 3 months prior to study enrollment
  • Consent provided

Age in the registry: 13 years to 21 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Istanbul University
Coordinator of this site? Confirm its status
IstanbulTurkey (Türkiye)Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.